Search Results - "Adashek, J."

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? by Adashek, Jacob J., Kato, Shumei, Ferrara, Roberto, Lo Russo, Giuseppe, Kurzrock, Razelle

“…There are currently seven approved immune checkpoint inhibitors (ICIs) for the treatment of various cancers. These drugs are associated with profound, durable…”
Get full text

Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening by Adashek, Jacob J, Janku, Filip, Kurzrock, Razelle

“…With the addition of molecular testing to the oncologist's diagnostic toolbox, patients have benefitted from the successes of gene- and immune-directed…”
Get full text

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy by Kato, Shumei, Kim, Ki Hwan, Lim, Hyo Jeong, Boichard, Amelie, Nikanjam, Mina, Weihe, Elizabeth, Kuo, Dennis J., Eskander, Ramez N., Goodman, Aaron, Galanina, Natalie, Fanta, Paul T., Schwab, Richard B., Shatsky, Rebecca, Plaxe, Steven C., Sharabi, Andrew, Stites, Edward, Adashek, Jacob J., Okamura, Ryosuke, Lee, Suzanna, Lippman, Scott M., Sicklick, Jason K., Kurzrock, Razelle

“…Next-generation sequencing (NGS) can identify novel cancer targets. However, interpreting the molecular findings and accessing drugs/clinical trials is…”
Get full text

Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers by Nelson, Blessie Elizabeth, Adashek, Jacob J, Sheth, Aakash Akshay, Subbiah, Vivek

“…Radiotherapy is a pillar of cancer treatment, which has historically been used primarily to treat localized disease with curative intent. With the increasing…”
Get full text

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics by Tateo, Valentina, Marchese, Paola Valeria, Mollica, Veronica, Massari, Francesco, Kurzrock, Razelle, Adashek, Jacob J

“…(1) Background: The oncology field has drastically changed with the advent of precision medicine, led by the discovery of druggable genes or immune targets…”
Get full text

Cancer: slaying the nine-headed Hydra by Adashek, J.J., Subbiah, V., Westphalen, C.B., Naing, A., Kato, S., Kurzrock, R.

“…Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines…”
Get full text

Hallmarks of RET and Co-occuring Genomic Alterations in RET -aberrant Cancers by Adashek, Jacob J, Desai, Aakash P, Andreev-Drakhlin, Alexander Y, Roszik, Jason, Cote, Gilbert J, Subbiah, Vivek

“…Activating receptor-tyrosine kinase rearranged during transfection mutations and fusions are potent drivers of oncogenesis. The recent FDA approvals of highly…”
Get full text

High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting by Joshi, Rushikesh S., Boichard, Amelie, Adashek, Jacob J., Kurzrock, Razelle

“…Next-generation sequencing data is fundamentally changing the clinical management of patients with cancer. The most frequent genomic alterations in malignancy…”
Get full text

Caring for the caregiver: a systematic review characterising the experience of caregivers of older adults with advanced cancers by Adashek, Jacob J, Subbiah, Ishwaria M

“…The steady advances in oncology bring a host of therapeutic options for older adults (≤65 years old) with cancer. As these patients experience this…”
Get full text

The paradox of cancer genes in non-malignant conditions: implications for precision medicine by Adashek, Jacob J, Kato, Shumei, Lippman, Scott M, Kurzrock, Razelle

“…Next-generation sequencing has enabled patient selection for targeted drugs, some of which have shown remarkable efficacy in cancers that have the cognate…”
Get full text

Multi‐omic analysis in carcinoma of unknown primary (CUP): therapeutic impact of knowing the unknown by Kato, Shumei, Gumas, Sophia, Adashek, Jacob J., Okamura, Ryosuke, Lee, Suzanna, Sicklick, Jason K., Kurzrock, Razelle

“…Carcinoma of unknown primary (CUP) is a difficult‐to‐manage malignancy. Multi‐omic profiles and treatment outcome vs. degree of precision matching were…”
Get full text

Home-run trials for rare cancers: giving the right drug(s) to the right patients at the right time and in the right place by Adashek, Jacob J., Kurzrock, Razelle

“…In oncology clinical trials, many patients spend their final months at a central clinical trial facility far from home for “mandatory” protocol…”
Get full text

Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact? by Adashek, Jacob J, Subbiah, Ishwaria M, Matos, Ignacio, Garralda, Elena, Menta, Arjun K, Ganeshan, Dhakshina Moorthy, Subbiah, Vivek

“…Immunotherapy (IO) has altered the therapeutic landscape for multiple cancers. There are emerging data from retrospective studies on a subset of patients who…”
Get more information

Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer by Adashek, Jacob J, Pandya, Chinmayi, Maragakis, Nicholas J, De, Pradip, Cohen, Philip R, Kato, Shumei, Kurzrock, Razelle

“…Neuregulin-1 (NRG1) is implicated in both cancer and neurologic diseases such as amyotrophic lateral sclerosis (ALS); however, to date, there has been little…”
Get full text

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer by Adashek, Jacob J, Jain, Rohit K, Zhang, Jingsong

“…The approval of upfront abiraterone for castration-sensitive prostate cancer and the approval of enzalutamide and apalutamide for non-metastatic…”
Get full text

Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload by Kondrashov, Aleksei, Sapkota, Surendra, Sharma, Aditya, Riano, Ivy, Kurzrock, Razelle, Adashek, Jacob J

“…Antibody–drug conjugates (ADCs) are at the forefront of the drug development revolution occurring in oncology. Formed from three main components—an antibody, a…”
Get full text

On target methods to induce abscopal phenomenon for Off‐Target effects: From happenstance to happenings by Nelson, Blessie Elizabeth, Adashek, Jacob J., Lin, Steven H., Subbiah, Vivek

“…Although the “abscopal phenomenon” has been described several decades ago, this phenomenon lately has been obtaining momentous traction with the dawn of…”
Get full text

Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer by Adashek, Jacob J., Arroyo-Martinez, Yadis, Menta, Arjun K., Kurzrock, Razelle, Kato, Shumei

“…Gastric cancer remains third leading cause of global cancer mortality and is the fifth most common type of cancer in the United States. A select number of…”
Get full text

Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia by Adashek, Jacob J., Brodsky, Max, Levis, Mark J.

“…The cytogenetic abnormality inv(2)(p23q13) in acute myeloid leukemia (AML) results in a fusion of RANBP2 with ALK. This fusion makes ALK constitutively active…”
Get full text

Genomics and Immunomics in the Treatment of Urothelial Carcinoma by Mollica, Veronica, Massari, Francesco, Rizzo, Alessandro, Ferrara, Roberto, Menta, Arjun K, Adashek, Jacob J

“…Urothelial carcinoma is a complex cancer with genomic immunomic drivers that have prognostic and predictive treatment implications. Identifying potential…”
Get full text